Japanese recommendation moves edoxaban closer to first approval
This article was originally published in Scrip
Daiichi Sankyo's oral Factor Xa inhibitor edoxaban has received its first approval recommendation worldwide, in Japan as Lixiana for the prevention of venous thromboembolism (VTE) after major orthopaedic surgery.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.